Russell Investments Group
NBSE

Russell Investments Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Russell Investments Group’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,083
Closed -$160K – 3319
2021
Q1 		$160K Hold
1,083
– – ﹤0.01% 2886
2020
Q4 		$151K Sell
1,083
-647
-37% -$105K ﹤0.01% 2813
2020
Q3 		$262K Buy
1,730
+1,418
+454% +$231K ﹤0.01% 2665
2020
Q2 		$54K Buy
+312
New +$52.2K ﹤0.01% 2981

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group's NBSE Position: Q2 2021 in Review

Russell Investments Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2021, closing a stake of 1,083 shares — an estimated $160K sold.

Russell Investments Group first reported a position in NBSE in Q2 2020 and held it in 4 quarters. The position peaked at $262K in Q3 2020. 57 funds tracked by Wall St. Rank hold NBSE as of Q2 2021.

  • Russell Investments Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Russell Investments Group sold 1,083 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $160K.
  • Russell Investments Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Russell Investments Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $262K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Russell Investments Group's 13F filing for Q2 2021, filed 4 Aug 2021.